Carlos Silva Rondon, MD

Articles by Carlos Silva Rondon, MD

$Two hematologic oncologists debated the clinical trade-offs of CAR T-cell therapy vs bispecific antibodies in relapsed/refractory follicular lymphoma.$

Considering CAR T vs Bispecific Antibodies in R/R Follicular Lymphoma

ByNikesh Shah, MD,Carlos Silva Rondon, MD

July 21st 2026

Two hematologic oncologists debated the clinical trade-offs of CAR T-cell therapy vs bispecific antibodies in relapsed/refractory follicular lymphoma.

Carlos Silva Rondon, MD

Articles by Carlos Silva Rondon, MD

Considering CAR T vs Bispecific Antibodies in R/R Follicular Lymphoma

Latest Updated Articles

Trending on CancerNetwork

Study Redefines Functional High-Risk Multiple Myeloma in Modern-Therapy Era

Half a Year Into the Breast Biopsy Needle Shortage, Clinicians Lean on Networks, Not Workarounds

First-in-Human mKRAS Vaccine Elicits Durable T-Cell Responses in High-Risk PDAC

Clinical Scenario - Long-Term Toxicity Management in HER2-Positive Metastatic Breast Cancer

Resistance Biology: MARIPOSA vs. FLAURA2 Reshaping Debate